Évolution du traitement de sortie après hospitalisation pour syndrome coronaire aigu en France entre 1995 et 2000 : données des études Usik 1995, Prévenir 1 et 2 et Usic 2000

@article{Danchin2003volutionDT,
  title={{\'E}volution du traitement de sortie apr{\`e}s hospitalisation pour syndrome coronaire aigu en France entre 1995 et 2000 : donn{\'e}es des {\'e}tudes Usik 1995, Pr{\'e}venir 1 et 2 et Usic 2000},
  author={Nicolas Danchin and Guy Hanania and O Grenier and Laurent Vaur and E. Am{\'e}lineau and P. Gu{\'e}ret and Didier Blanchard and Jean Ferri{\`e}res and N. Gen{\`e}s and Jean M. Lablanche and Christelle Cantet and J. P. Cambou},
  journal={Annales De Cardiologie Et D Angeiologie},
  year={2003},
  volume={52},
  pages={1-6}
}
Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe.
  • P. Vranckx, E. Boersma, P. Serruys
  • Medicine, Biology
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
  • 2011
TLDR
There is an unmet clinical need in primary and secondary CV prevention in Europe and patients requiring PCI are an important target population in whom lifestyle changes and aggressive secondary preventative measures should be aimed.
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
  • K. Kotseva, D. Wood, G. Backer, D. Bacquer, K. Pyörälä, U. Keil
  • Medicine
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
  • 2009
TLDR
It is shown that large proportions of coronary patients do not achieve the lifestyle, risk factor and therapeutic targets for cardiovascular disease prevention, and there is still considerable potential throughout Europe to raise standards of preventive care.
Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult CHD patients in Finland: results from a large national database between 2000 and 2006
  • T. Ahola, I. Kantola, A. Jula
  • Medicine, Political Science
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
  • 2010
TLDR
Utilization of antihypertensive agents (especially angiotensin receptor blockers) and lipid-lowering drugs has increased remarkably by the end of 2006, however, the treatments are still far from optimal.
Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study).
TLDR
The GRACE risk score predicts early and 5 year death and CVD/MI as high in patients following non-ST MI and UA as seen following STEMI, and the findings highlight the importance of pursuing novel approaches to diminish long-term risk.
...
1
2
3
...

References

SHOWING 1-10 OF 30 REFERENCES
Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey
TLDR
In this national French survey, patients treated with percutaneous coronary interventions were more likely to receive secondary preventive drugs than patients receiving medical treatment alone.
Optimizing the Prescription of Statins After an Acute Coronary Syndrome: The Influence of Coronary Angioplasty and Total Cholesterol Levels
TLDR
A more aggressive use of statin therapy was observed in the patients in whom a coronary angioplasty was performed even if TC levels were not assayed and in patients without an in-hospital TC check, which independently predicted by multivariate analysis an increased or a decreased likelihood of prescription of statins.
[Characteristics of patients hospitalized for myocardial infarction in France with respect to left ventricular dysfunction. Results of the USIK study].
Patients admitted in coronary care units, in november 1995, for confirmed acute myocardial infarction within 48 hours of symptoms onset were included in this study. The choice of measurement of left
Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group.
TLDR
These results support the use of ACE inhibitors early in the treatment of acute MI, either to a wide range of patients or selectively in patients with anterior MI and in those at increased risk of death.
Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes
TLDR
Contrary to expectations, invasive procedures for acute coronary syndromes are associated with higher rates of prescription of pharmacological secondary prevention.
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
TLDR
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure.
...
1
2
3
...